

CLEVELAND BIOLABS INC  
Form 8-K  
August 12, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): August 12, 2015**

**Cleveland BioLabs, Inc.**  
(Exact Name of Issuer as Specified in Charter)

<b>DELAWARE</b> (State or Other Jurisdiction of Incorporation or Organization)	<b>001-32954</b> (Commission File Number)	<b>20-0077155</b> (I.R.S. Employer Identification Number)
--	--	---

**73 High Street  
Buffalo, NY 14203**  
(Address of Principal Executive Offices and zip code)

**(716) 849-6810**  
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Conditions.**

On August 12, 2015, Cleveland BioLabs, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2015. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

**Item 9.01 Financial Statements and Exhibits.**

(d)

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release titled “Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress”, dated August 12, 2015

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cleveland BioLabs, Inc.**

Date: August 12, 2015 By: /s/ YAKOV KOGAN  
Name: Yakov Kogan  
Title: Chief Executive Officer